Skip to main content

Table 1 Baseline characteristics of anaplastict thyroid cancer (ATC) patients treated with pembrolizumab added as a salvage therapy to kinase inhibitor therapy

From: Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

 

N = 12

Median Age at treatment start, years (range)

60 (47–84)

Gender, n (%)

 Men

 Women

8 (67)

4 (33)

Ethnicity, n (%)

  Caucasian

  Asian

  Black

9 (75)

2 (16)

1 (9)

Stage at Diagnosis, n (%)

  IVA

  IVB

  IVC

0 (0)

3 (25)

9 (75)

Pathology, n (%)

  ATC only

  Papillary thyroid cancer + ATC

  Poorly differentiated thyroid cancer + ATC

  Follicular thyroid cancer +ATC

4 (33)

4 (33)

3 (25)

1 (9)

PD-L1 status, n (%)

  < 10%

 11–50%

 51–100%

10 (83)

2 (20)

4 (40)

4 (40)

Performance Status, n (%)

  ECOG 0

  ECOG 1

  ECOG 2

2 (16)

6 (50)

4 (33)

Previous Treatment for ATC, n (%)a

  Surgery, n (%)

  Radiation/chemosensitizing, n (%)

  Bridging Chemotherapy, n (%)b

5 (41)

6 (50)

3 (25)

Targeted therapyc, n (%)

  Lenvatinib

  Dabrafenib + trametinib

  Trametinib alone

5 (41)

6 (50)

1 (9)

  1. aPatients received more than 1 modality of therapy
  2. bChemotherapy as a bridging therapy while awaiting targeted therapy
  3. cAll patients with BRAFV600E mutations were treated with dabrafenib + trametinib